Mereo Biopharma’s Strategic Progress and Promising Pipeline Drive Buy Rating
Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report) and keeping the ...
manilatimes9d
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
Cambridge, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...
Finanznachrichten10d
Mereo BioPharma Group plc: Mereo BioPharma Provides Update on Lead Clinical Programs
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, ...
TMCnet10d
Mereo BioPharma Provides Update on Lead Clinical Programs
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its lead clinical programs, ...